Target intelligence / Profile preview

Exon 53 of dystrophin pre-mRNA

Molecular classification
Other (pre-mRNA exon sequence), Genetic element (as part of the DMD gene pre-mRNA), Not a protein/receptor/enzyme/ion channel/transcription factor
01

Overview

Exon 53 of dystrophin pre-mRNA is one of 79 protein-coding exons in the DMD gene pre-mRNA that, when correctly spliced, enables the production of full-length dystrophin—a structural protein essential for muscle fiber stability. In Duchenne muscular dystrophy, certain exon deletions disrupt the reading frame, causing the absence of functional dystrophin. Drugs such as viltolarsen and golodirsen are designed to bind exon 53 in the pre-mRNA and induce its skipping during splicing, restoring the mRNA's reading frame and enabling the synthesis of a truncated but functional dystrophin protein, thereby providing a molecularly guided therapy for a subset of DMD patients

Other names
Exon 53 of the DMD geneDMD exon 53
02

Mechanism of action

Antisense oligonucleotide-mediated exon skipping: Synthetic oligonucleotides bind to exon 53 of dystrophin pre-mRNA, hiding it from the spliceosome and causing its exclusion from the mature mRNA, restoring the transcript’s reading frame and enabling production of a truncated but partially functional dystrophin protein

03

Biological functions

Pre-mRNA processing (alternative and canonical splicing)Production of functional dystrophin protein, when appropriately splicedMutation or exclusion affects maintenance of muscle cell membrane stability via dystrophin
04

Disease associations

Muscular dystrophy (specifically, mutations/exon deletions lead to Duchenne muscular dystrophy; altering splicing can produce Becker-like phenotypes)Other (dystrophin is also implicated in some cardiomyopathies due to its role in muscle integrity)
05

Safety considerations

Class-specific risks of antisense oligonucleotides (e.g., renal toxicity, immune responses, injection site reactions)Potential for unintended splicing events or off-target effectsUnknown long-term effects of partial dystrophin restoration
06

Interacting drugs

Viltolarsen

3 more in the full profile.

07

Biomarkers

Rate or efficiency of exon 53 skipping (quantified by RT-PCR)Restored dystrophin protein levels (quantified by immunoblot/Western blot)

Beyond the preview

Go deeper on Exon 53 of dystrophin pre-mRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exon 53 of dystrophin pre-mRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call